Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Regional scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Liver Metastases treatment Market Variables, Trends, and Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.1.1 Liver Cancer Treatment Market
3.2 Penetration and Growth Prospect Mapping for Treatment Type, 2022
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Approval of targeted therapy for the treatment of Liver Metastases
3.3.2 Market Restraint Analysis
3.3.2.1 Technological advancements for early diagnosis of cancer
3.4 Market Analysis Tools
3.4.1 Industry Analysis: Porter’s
3.4.1.1 Threat of new entrants
3.4.1.2 Bargaining power of buyers
3.4.1.3 Competitive rivalry
3.4.1.4 Threat of substitutes
3.4.1.5 Bargaining power of suppliers
3.4.2 Industry Analysis: PESTEL
3.4.2.1 Political & Legal
3.4.2.2 Economical
3.4.2.3 Technological
Chapter 4 Liver Metastases treatment Market: Segment Analysis, by Treatment Type, 2018 – 2030 (USD Million)
4.1 Liver Metastases treatment Market: Treatment Type Movement Analysis
4.1.1 Chemotherapy
4.1.1.1 Chemotherapy Market Estimates and Forecast, 2018 – 2030 (USD Million)
4.1.2 Targeted Therapy
4.1.2.1 Targeted Therapy Market Estimates and Forecast, 2018 – 2030 (USD Million)
4.1.3 Immunotherapy
4.1.3.1 Immunotherapy Market Estimates and Forecast, 2018 – 2030 (USD Million)
Chapter 5 Liver Metastases treatment Market: Segment Analysis, by Primary Cancer, 2018 – 2030 (USD Million)
5.1 Liver Metastases treatment Market: Primary Cancer Movement Analysis
5.1.1 Colorectal Cancer
5.1.1.1 Colorectal Cancer Market Estimates and Forecast, 2018 – 2030 (USD Million)
5.1.2 Breast Cancer
5.1.2.1 Breast Cancer Market Estimates and Forecast, 2018 – 2030 (USD Million)
Chapter 6 Liver Metastases treatment Market: Segment Analysis, by Distribution Channel, 2018 – 2030 (USD Million)
6.1 Liver Metastases treatment Market: Distribution Channel Movement Analysis
6.1.1 Hospital Pharmacies
6.1.1.1 Hospital Pharmacies Market Estimates and Forecast, 2018 – 2030 (USD Million)
6.1.2 Specialty Pharmacies
6.1.2.1 Specialty Pharmacies Market Estimates and Forecast, 2018 – 2030 (USD Million)
Chapter 7 Liver Metastases Treatment Market: Regional Estimates and Trend Analysis, by Type, Product, & Application
7.1 North America
7.1.1 SWOT Analysis
7.1.1.1 North America Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.1.3 Canada
7.1.3.1 Key Country Dynamics
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2 Europe
7.2.1 SWOT Analysis:
7.2.1.1 Europe Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.2 Germany
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Germany Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.3 U.K.
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 U.K. Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.7 Denmark
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Denmark Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.8 Sweden
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Sweden Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.9 Norway
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Norway Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.9.7 Rest of Europe Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3 Asia Pacific
7.3.1 SWOT Analysis:
7.3.1.1 Asia Pacific Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.2 Japan
7.3.2.1 Key Country Dynamics
7.3.2.2 Target Disease Prevalence
7.3.2.3 Competitive Scenario
7.3.2.4 Regulatory Framework
7.3.2.5 Reimbursement Scenario
7.3.2.6 Japan Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.3 China
7.3.3.1 Key Country Dynamics
7.3.3.2 Target Disease Prevalence
7.3.3.3 Competitive Scenario
7.3.3.4 Regulatory Framework
7.3.3.5 Reimbursement Scenario
7.3.3.6 China Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.4 India
7.3.4.1 Key Country Dynamics
7.3.4.2 Target Disease Prevalence
7.3.4.3 Competitive Scenario
7.3.4.4 Regulatory Framework
7.3.4.5 Reimbursement Scenario
7.3.4.6 India Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.5 Australia
7.3.5.1 Key Country Dynamics
7.3.5.2 Target Disease Prevalence
7.3.5.3 Competitive Scenario
7.3.5.4 Regulatory Framework & Reimbursement Scenario
7.3.5.5 Australia Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.6 Thailand
7.3.6.1 Key Country Dynamics
7.3.6.2 Target Disease Prevalence
7.3.6.3 Competitive Scenario
7.3.6.4 Regulatory Framework & Reimbursement Scenario
7.3.6.5 Thailand Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.7 South Korea
7.3.7.1 Key Country Dynamics
7.3.7.2 Target Disease Prevalence
7.3.7.3 Competitive Scenario
7.3.7.4 Regulatory Framework & Reimbursement Scenario
7.3.7.5 South Korea Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.7.6 Rest of Asia Pacific Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4 Latin America
7.4.1 SWOT Analysis:
7.4.1.1 Latin America Liver Metastases treatment market estimates and forecasts, 2018 – 2030 (USD Million)
7.4.2 Brazil
7.4.2.1 Key Country Dynamics
7.4.2.2 Target Disease Prevalence
7.4.2.3 Competitive Scenario
7.4.2.4 Regulatory Framework
7.4.2.5 Reimbursement Scenario
7.4.2.6 Brazil Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.3 Mexico
7.4.3.1 Key Country Dynamics
7.4.3.2 Target Disease Prevalence
7.4.3.3 Competitive Scenario
7.4.3.4 Regulatory Framework
7.4.3.5 Reimbursement Scenario
7.4.3.6 Mexico Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.4 Argentina
7.4.4.1 Key Country Dynamics
7.4.4.2 Target Disease Prevalence
7.4.4.3 Competitive Scenario
7.4.4.4 Regulatory Framework
7.4.4.5 Reimbursement Scenario
7.4.4.6 Argentina Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.4.7 Rest of Latin America Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5 Middle East & Africa (MEA)
7.5.1 SWOT Analysis:
7.5.1.1 Middle East & Africa Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.2 South Africa
7.5.2.1 Key Country Dynamics
7.5.2.2 Target Disease Prevalence
7.5.2.3 Competitive Scenario
7.5.2.4 Regulatory Framework
7.5.2.5 Reimbursement Scenario
7.5.2.6 South Africa Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.3 Saudi Arabia
7.5.3.1 Key Country Dynamics
7.5.3.2 Target Disease Prevalence
7.5.3.3 Competitive Scenario
7.5.3.4 Regulatory Framework
7.5.3.5 Reimbursement Scenario
7.5.3.6 Saudi Arabia Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.4 UAE
7.5.4.1 Key Country Dynamics
7.5.4.2 Target Disease Prevalence
7.5.4.3 Competitive Scenario
7.5.4.4 Regulatory Framework
7.5.4.5 Reimbursement Scenario
7.5.4.6 UAE Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.5 Kuwait
7.5.5.1 Key Country Dynamics
7.5.5.2 Target Disease Prevalence
7.5.5.3 Competitive Scenario
7.5.5.4 Regulatory Framework
7.5.5.5 Reimbursement Scenario
7.5.5.6 Kuwait Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.5.7 Rest of MEA Liver Metastases treatment Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 New Product Launch
8.1.2 Merger and Acquisition
8.1.3 Licensing Agreements
8.1.4 Conferences and Campaigns
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List of Key Distributors and Channel Partners
8.3.2 Key Customers
8.4 Public Companies
8.4.1 Key Company Market Share Analysis, 2022
8.4.2 Company Market Position Analysis
8.4.3 Heat Map Analysis
8.4.4 Competitive Dashboard Analysis
8.4.4.1 Market Differentiators
8.5 Private Companies
8.5.1 List of Key Emerging Companies
8.5.2 Regional Network Map
8.6 Company Profiles
8.6.1. F. Hoffmann – La Roche Ltd.
8.6.1.1 Company Overview
8.6.1.2 Financial Performance
8.6.1.3 Product Benchmarking
8.6.1.4 Strategic Initiatives
8.6.2 AstraZeneca
8.6.2.1 Company Overview
8.6.2.2 Financial Performance
8.6.2.3 Product Benchmarking
8.6.2.4 Strategic Initiatives
8.6.3 Bayer AG
8.6.3.1 Company Overview
8.6.3.2 Financial Performance
8.6.3.3 Product Benchmarking
8.6.3.4 Strategic Initiatives
8.6.4 Eli Lilly and Company
8.6.4.1 Company Overview
8.6.4.2 Financial Performance
8.6.4.3 Product Benchmarking
8.6.4.4 Strategic Initiatives
8.6.5 Ono Pharmaceutical
8.6.5.1 Company Overview
8.6.5.2 Financial Performance
8.6.5.3 Product Benchmarking
8.6.5.4 Strategic Initiatives
8.6.6 Pfizer, Inc.
8.6.6.1 Company Overview
8.6.6.2 Financial Performance
8.6.6.3 Product Benchmarking
8.6.6.4 Strategic Initiatives
8.6.7 Bristol – Myers Squibb Company
8.6.7.1 Company Overview
8.6.7.2 Financial Performance
8.6.7.3 Product Benchmarking
8.6.7.4 Strategic Initiatives
8.6.8 Cadila Pharmaceuticals Ltd.
8.6.8.1 Company Overview
8.6.8.2 Financial Performance
8.6.8.3 Product Benchmarking
8.6.8.4 Strategic Initiatives